We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

104 hedge funds and large institutions have $360M invested in VistaGen Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 12

21% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 29

3% more funds holding

Funds holding: 101 → 104 (+3)

0.12% more ownership

Funds ownership: 2.15% → 2.27% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less capital invested

Capital invested by funds: $387M → $360M (-$26.5M)

93% less call options, than puts

Call options by funds: $50K | Put options by funds: $704K

Holders
104
Holders Change
+3
Holders Change %
+2.97%
% of All Funds
1.82%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
35
Reduced
29
Closed
12
Calls
$50K
Puts
$704K
Net Calls
-$654K
Net Calls Change
-$654K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$13.9M
2
CC
Commodore Capital
New York
+$5.19M
3
Goldman Sachs
Goldman Sachs
New York
+$3.01M
4
EGI
EAM Global Investors
California
+$1.84M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$1.39M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$4.51M
2
IC
Ikarian Capital
Texas
-$915K
3
SFM
Sphera Funds Management
Israel
-$741K
4
SB
Samsara BioCapital
California
-$707K
5
SSA
Schonfeld Strategic Advisors
New York
-$554K
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
26
Samsara BioCapital
California
$1.34M -$707K -8,132 -33%
Charles Schwab
27
Charles Schwab
California
$1.33M +$31.1K +358 +2%
Millennium Management
28
Millennium Management
New York
$1.22M +$778K +8,955 +152%
HS
29
HighVista Strategies
Massachusetts
$1.2M +$377K +4,338 +42%
SSA
30
Schonfeld Strategic Advisors
New York
$1.16M -$554K -6,370 -31%
CAM
31
ClariVest Asset Management
California
$804K -$4.61K -53 -0.5%
State of Wisconsin Investment Board
32
State of Wisconsin Investment Board
Wisconsin
$678K – – –
Rafferty Asset Management
33
Rafferty Asset Management
New York
$676K +$715K +8,223 New
AA
34
ALPS Advisors
Colorado
$648K +$144K +1,660 +27%
UBS Group
35
UBS Group
Switzerland
$585K +$617K +7,099 +88,738%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$544K +$521K +6,001 +968%
JP Morgan Chase
37
JP Morgan Chase
New York
$536K -$37.4K -430 -6%
AQR Capital Management
38
AQR Capital Management
Connecticut
$497K +$208K +2,391 +65%
OFA
39
Oak Family Advisors
Illinois
$483K +$19.3K +222 +4%
Citigroup
40
Citigroup
New York
$480K +$481K +5,531 +1,819%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$439K +$51K +587 +12%
HighTower Advisors
42
HighTower Advisors
Illinois
$372K – – –
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$368K -$86.1K -991 -18%
DADC
44
D.A. Davidson & Co
Montana
$349K -$11.6K -133 -3%
Citadel Advisors
45
Citadel Advisors
Florida
$346K +$331K +3,805 +954%
Deutsche Bank
46
Deutsche Bank
Germany
$326K -$196K -2,261 -36%
Invesco
47
Invesco
Georgia
$309K +$79.5K +915 +32%
AIG
48
American International Group
New York
$291K -$2.87K -33 -0.9%
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$284K -$19.5K -224 -6%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$283K -$466K -5,366 -61%
1
2
3 4 5

VTGN Hedge Fund Activity: Q3 2021 in Review

104 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2021, worth a combined $360M — down 6.8% from $387M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new VTGN positions and 12 closed out — a net gain of 6 holders — while 35 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $13.9M. The largest seller was OrbiMed, cutting an estimated $4.51M.

  • 104 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2021, up from 101 in Q2 2021.
  • Funds reported $360M of VistaGen Therapeutics stock for Q3 2021, down 6.8% quarter-over-quarter.
  • 18 funds opened new VistaGen Therapeutics positions in Q3 2021 and 12 closed out, a net change of +6 holders.
  • The largest VistaGen Therapeutics buyer in Q3 2021 was State Street, an estimated $13.9M added.
  • The largest VistaGen Therapeutics seller in Q3 2021 was OrbiMed, an estimated $4.51M sold.

Based on aggregated 13F filings for Q3 2021.